ArticleBlood2016
Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.
Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?Clinical lymphoma, myeloma & leukemia · 2026Review
- Generic competition and price developments in the USA, Germany and Switzerland (2007-2023): a longitudinal observational study.BMJ public health · 2025Article
- The high costs of anticancer therapies in the USA: challenges, opportunities and progress.Nature reviews. Clinical oncology · 2024Review
- Descriptive Trends in Medicaid Antipsychotic Prescription Claims and Expenditures, 2016 - 2021.The journal of behavioral health services & research · 2024Article
- The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Evaluation of the Generic Drug User Fee Act (GDUFA) Program for Fiscal Years 2013-2022.The AAPS journal · 2024Article
- Article
- Predictive Potential of BCS and Pharmacokinetic Parameters on Study Outcome: Analysis of 198 In Vivo Bioequivalence Studies.European journal of drug metabolism and pharmacokinetics · 2023Article
- A dashboard for exploring clinical trials sponsorship and potential virtual monopolies.JAMIA open · 2021Article
- Drugs Becoming Generics-The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients.International journal of environmental research and public health · 2021Article
- US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate.JAMA internal medicine · 2020Article
- Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.JCO global oncology · 2020Review
- Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib.Journal of pharmaceutical policy and practice · 2020Review
- The Challenge of High Drug Prices in America: Cost Disclosure in Direct-to-Consumer Advertising May Offer a Solution.American health & drug benefits · 2019Article
- Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs.PloS one · 2019Article
- The high price of anticancer drugs: origins, implications, barriers, solutions.Nature reviews. Clinical oncology · 2017Review
- Review
- Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.Nature reviews. Clinical oncology · 2016Article
- An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).Perspectives in clinical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
High cancer drug prices are influenced by the availability of generic cancer drugs in a timely manner. Several strategies have been used to delay the availability of affordable generic drugs into the United States and world markets. These include reverse payment or pay-for-delay patent settlements, authorized generics, product hopping, lobbying against cross-border drug importation, buying out the competition, and others. In this forum, we detail these strategies and how they can be prevented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.